Individualized or Uniform De-Escalation Strategies for Antiplatelet Therapy in Acute Coronary Syndrome: A Review of
Oumaima El Alaoui El Abdallaoui1, Dániel Tornyos2, Réka Lukács2
1Doctoral School of Health Sciences, Faculty of Health Sciences, University of Pécs, 7621 Pécs, Hungary.
Abstract:
This comprehensive literature review assessed the effectiveness of precision medicine approaches in individualizing P2Y12 de-escalation strategies, such as platelet function testing guidance, genetic testing guidance, and uniform de-escalation, for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Analyzing six trials with a total of 13,729 patients, the cumulative analyses demonstrated a significant reduction in major adverse cardiac events (MACE), net adverse clinical events (NACE), and major and minor bleeding events with P2Y12 de-escalation. Specifically, the analysis found a 24% reduction of MACE and a 22% reduction of adverse event risk (relative risk (RR) 0.76, 95% confidence interval (CI): 0.71-0.82, and RR: 0.78, 95% CI 0.67-0.92, respectively). Reductions in bleeding events were highest with uniform unguided de-escalation, followed by guided de-escalations, while ischemic event rates were similarly lower across all three strategies. Although the review highlights the potential of individualized P2Y12 de-escalation strategies to offer a safer alternative to the long-term potent P2Y12 inhibitor-based dual antiplatelet therapy, it also indicates that laboratory-guided precision medicine approaches may not yet offer the expected benefits, necessitating further research to optimize individualized strategies and evaluate the potential of precision medicine approaches in this context.
Insights
Precision medicine strategies for P2Y12 de-escalation in acute coronary syndrome (ACS) patients significantly reduced major adverse cardiac events (MACE) and bleeding. Uniform de-escalation showed the greatest bleeding reduction, while guided approaches also proved beneficial.
Area of Science:
- Cardiology
- Pharmacogenomics
- Precision Medicine
Background:
- Dual antiplatelet therapy (DAPT) with P2Y12 inhibitors is standard for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
- Long-term potent P2Y12 inhibition increases bleeding risk, prompting investigation into de-escalation strategies.
Purpose of the Study:
- To assess the effectiveness of individualized P2Y12 de-escalation strategies in ACS patients post-PCI.
- To compare guided (platelet function testing, genetic testing) versus uniform de-escalation approaches.
Main Methods:
- A comprehensive literature review of six trials involving 13,729 patients.
- Cumulative analysis of major adverse cardiac events (MACE), net adverse clinical events (NACE), and bleeding events.
Main Results:
- P2Y12 de-escalation significantly reduced MACE (24% reduction) and overall adverse events (22% reduction).
- Bleeding event reductions were highest with uniform unguided de-escalation, followed by guided strategies.
- Ischemic event rates were similarly low across all de-escalation strategies.
Conclusions:
- Individualized P2Y12 de-escalation offers a safer alternative to standard DAPT for ACS patients.
- Laboratory-guided precision medicine approaches may require further optimization to realize full benefits.
- Further research is needed to refine individualized strategies and evaluate precision medicine's role in P2Y12 de-escalation.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management
01:27Peripheral Artery Disease III: Interprofessional Care